Summary: Seven non-splenectomized patients with chronic refractory idiopathic thrombocytopenic purpura were treated with danazol 800 mg daily. All were glucocorticoid failures and four were refractory to all additional previous therapy. Five patients benefited from danazol and in two sustained normal platelet counts, for over 44 and 51 months, were observed. We conclude that danazol is useful for long term management of otherwise refractory idiopathic thrombocytopenic purpura. The advantage of danazol over splenectomy as a first line treatment in steroid failure is suggested.
Introduction
Thrombocytopenia in most patients with idiopathic thrombocytopenic purpura (ITP) responds to steroids."-3 Splenectomy is considered the treatment of choice in steroid failures,",4'5 followed by immunosuppressive therapy when needed.'"2 Danazol, a derivative of ethinyl testosterone, is a synthetic attenuated androgen with reduced masculinizing capacity, initially formulated for the treatment of endometriosis.2'3'6-8 Favourable results of danazol therapy in refractory ITP were first described by Ahn et al. in 1983.6 In the few reports published since, the authors were almost equally divided between those who achieved similar results8-"0 and those who failed to show a significant response. 3 
